Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN versus LODINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN versus LODINE.
Aspirin vs LODINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) via acetylation, reducing prostaglandin and thromboxane A2 synthesis. Also activates lipoxin biosynthesis (inflammation resolution).
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
325-650 mg PO q4-6h prn; max 4 g/day
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
30 minutes for aspirin (parent drug); salicylic acid: 2-3 hours after low doses, 15-30 hours after high doses due to saturable metabolism and renal reabsorption. Clinical context: prolonged half-life in overdose, renal impairment, and elderly patients.
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Renal excretion of salicylates (75-85% as salicyluric acid, 10% as free salicylic acid, 5-10% as glucuronide conjugates); dose-dependent, with renal clearance decreasing at higher doses due to saturation of metabolic pathways. Biliary/fecal elimination is minimal (<5%).
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Category C
Category C
NSAID / Antiplatelet
NSAID